Praxis Precision Medicines, Inc.
PRAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689548
No open-market purchases or sales by Praxis Precision Medicines, Inc. insiders were filed in the last 90 days; 309 institutions reported holding it in 13F filings for Q2 2026, worth $11.3B in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Praxis Precision Medicines, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 111
- +51 vs. Q4 2023
- Shares held
- 15.9M
- +7.90M (+98.6%) vs. Q4 2023
- Total value
- $971.3M
- +$792.7M (+443.9%) vs. Q4 2023
- New holders
- 58
- 30 more added
- Sold out
- 7
- 17 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 309 | $11.3B |
| Q1 2026 | 291 | $10.2B |
| Q4 2025 | 250 | $8.69B |
| Q3 2025 | 152 | $1.31B |
| Q2 2025 | 144 | $1.02B |
| Q1 2025 | 150 | $889.3M |
| Q4 2024 | 162 | $1.67B |
| Q3 2024 | 134 | $1.09B |
| Q2 2024 | 113 | $762.1M |
| Q1 2024 | 111 | $971.3M |
| Q4 2023 | 60 | $178.6M |
| Q3 2023 | 74 | $195.6M |
| Q2 2023 | 78 | $134.6M |
| Q1 2023 | 87 | $43.1M |
| Q4 2022 | 104 | $108.1M |
| Q3 2022 | 108 | $95.7M |
| Q2 2022 | 95 | $105.5M |
| Q1 2022 | 103 | $463.4M |
| Q4 2021 | 100 | $863.1M |
| Q3 2021 | 93 | $791.5M |
| Q2 2021 | 80 | $751.0M |
| Q1 2021 | 68 | $1.19B |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Praxis Precision Medicines, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 460,512 | $28.1M | 0.55% | +460,512 | New |
| PFM Health Sciences, LP | 477,605 | $29.1M | 1.45% | −178,943−27.3% | Reduced |
| Price T Rowe Associates Inc | 535,999 | $32.7M | 0.00% | +535,999 | New |
| Verition Fund Management LLC | 545,408 | $33.3M | 0.32% | −157,592−22.4% | Reduced |
| VR Adviser, LLC | 706,126 | $43.1M | 2.05% | +352,500+99.7% | Added |
| Vanguard Group Inc | 744,069 | $45.4M | 0.00% | +373,131+100.6% | Added |
| Perceptive Advisors LLC | 821,589 | $50.1M | 0.88% | +821,589 | New |
| Ra Capital Management, L.P. | 828,380 | $50.5M | 0.64% | +828,380 | New |
| Point72 Asset Management, L.P. | 954,140 | $58.2M | 0.17% | +261,888+37.8% | Added |
| Cormorant Asset Management, LP | 1,310,000 | $79.9M | 3.52% | +676,655+106.8% | Added |
| Adage Capital Partners GP, L.L.C. | 1,393,028 | $85.0M | 0.16% | +654,362+88.6% | Added |
| Blackstone Group Inc. | 0 | $0 | 0.00% | −70,273−100.0% | Sold out |
| Wildcat Capital Management, LLC | 0 | $0 | 0.00% | −16,756−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −15,705−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −11,481−100.0% | Sold out |
| DLD Asset Management, LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,157−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |